Emerging non-D2 receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways - Top-Institutions - MDSpire

Emerging non-D2 receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways

  • By

  • Yunxiang Wang

  • Jiajia Wang

  • Xiao Zhang

  • Xudong Liu

  • July 10, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Columbia University Department of Psychiatry/NewYork-Presbyterian Hospital
    Columbia University Department of Psychiatry/NewYork-Presbyterian Hospital

    New York, NY

    Key Differentiators

    • Psychiatry

  • #2

    Yale School of Medicine/Yale New Haven Hospital
    Yale School of Medicine/Yale New Haven Hospital

    New Haven, CT

    Key Differentiators

    • Psychiatry

Original Source(s)

Emerging non-D2 receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways

  • by Yunxiang Wang, Jiajia Wang, Xiao Zhang, Xudong Liu

  • July 10, 2026

Related Content

Ventricular cardiac magnetic resonance traits and schizophrenia risk: a UK Biobank and Mendelian randomization study

Infections and severe mental illness: a population-based matched cohort study

Association of MAP2 gene polymorphisms and altered expression with schizophrenia risk in a Chinese Han population